Innoviva Revenue 2012-2025 | INVA
Innoviva revenue from 2012 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
|
Innoviva Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $411 |
| 2024 | $359 |
| 2023 | $310 |
| 2022 | $331 |
| 2021 | $392 |
| 2020 | $337 |
| 2019 | $261 |
| 2018 | $261 |
| 2017 | $217 |
| 2016 | $134 |
| 2015 | $54 |
| 2014 | $8 |
| 2013 | $5 |
| 2012 | $6 |
| 2011 | $25 |
|
Innoviva Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-12-31 | $115 |
| 2025-09-30 | $108 |
| 2025-06-30 | $100 |
| 2025-03-31 | $89 |
| 2024-12-31 | $92 |
| 2024-09-30 | $90 |
| 2024-06-30 | $100 |
| 2024-03-31 | $77 |
| 2023-12-31 | $86 |
| 2023-09-30 | $67 |
| 2023-06-30 | $81 |
| 2023-03-31 | $76 |
| 2022-12-31 | $66 |
| 2022-09-30 | $67 |
| 2022-06-30 | $108 |
| 2022-03-31 | $90 |
| 2021-12-31 | $108 |
| 2021-09-30 | $98 |
| 2021-06-30 | $101 |
| 2021-03-31 | $86 |
| 2020-12-31 | $90 |
| 2020-09-30 | $89 |
| 2020-06-30 | $79 |
| 2020-03-31 | $79 |
| 2019-12-31 | $76 |
| 2019-09-30 | $66 |
| 2019-06-30 | $64 |
| 2019-03-31 | $55 |
| 2018-12-31 | $80 |
| 2018-09-30 | $62 |
| 2018-06-30 | $67 |
| 2018-03-31 | $52 |
| 2017-12-31 | $70 |
| 2017-09-30 | $49 |
| 2017-06-30 | $59 |
| 2017-03-31 | $40 |
| 2016-12-31 | $44 |
| 2016-09-30 | $33 |
| 2016-06-30 | $32 |
| 2016-03-31 | $24 |
| 2015-12-31 | $23 |
| 2015-09-30 | $14 |
| 2015-06-30 | $11 |
| 2015-03-31 | $7 |
| 2014-12-31 | $7 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $-1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $0 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $6 |
| 2012-09-30 | $1 |
| 2012-06-30 | $1 |
| 2012-03-31 | $127 |
| 2011-12-31 | $5 |
| 2011-09-30 | $6 |
| 2011-06-30 | $6 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |